Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 485-492

  Ekström, Mattias ^a   Liska, Jan ^a   Eriksson, Per ^a   Sverremark Ekström, Eva ^b   Tornvall, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Adipose tissue; CABG; Inflammation; PAI 1

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BIOPSY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; OMENTUM; OPEN HEART SURGERY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; UPREGULATION;

ABDOMINAL FAT; ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERY BYPASS; DNA, COMPLEMENTARY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OMENTUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTOPERATIVE COMPLICATIONS; RNA, MESSENGER; SUBCUTANEOUS FAT; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84865816648     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0822     Document Type: Article

References (41)

1. Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 2010; 55: 2701-2709.
2. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
3. Janand-Delenne B, Chagnaud C, Raccah D, et al. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-317.
4. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
5. Mertens I, Van der Planken M, Corthouts B, et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001; 33: 602-607.
6. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008; 100: 969-975.
7. Birgel M, Gottschling-Zeller H, Rohrig K, et al. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-1687.
8. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005; 54: 220-226.
9. Halleux CM, Declerck PJ, Tran SL, et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105.
10. Plomgaard P, Keller P, Keller C, et al. TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol 2005; 98: 2019-2023.
11. Rega G, Kaun C, Weiss TW, et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938-1945.
12. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97: 37-46.
13. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-1353.
14. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37: 1336-1340.
15. Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462.
16. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.
17. Akkus MN, Polat G, Yurtdas M, et al. Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J 2009; 50: 33-45.
18. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
19. Marcucci R, Brogi D, Sofi F, et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 2006; 92: 377-381.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
21. Aoki K, Nishino N, Baba S, et al. Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Surg Today 1994; 24: 1039-1043.
22. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001; 94: 74-78.
23. Sayer JW, Gutteridge C, Syndercombe-Court D, et al. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998; 32: 1962-1968.
24. Brull DJ, Sanders J, Rumley A, et al. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87: 252-255.
25. Tsai CS, Chen DL, Lin SJ, et al. TNF-alpha inhibits toll-like receptor 4 expression on monocytic cells via tristetraprolin during cardiopulmonary bypass. Shock 2009; 32: 40-48.
26. Ekstrom M, Halle M, Bjessmo S, et al. Systemic inflammation activates the nuclear factor-kappaB regulatory pathway in adipose tissue. Am J Physiol Endocrinol Metab 2010; 299: E234-240.
27. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
28. Mestries JC, Kruithof EK, Gascon MP, et al. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994; 5: 275-281.
29. Pretorius M, Murphey LJ, McFarlane JA, et al. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation 2003; 108: 3079-3083.
30. Gottschling-Zeller H, Birgel M, Rohrig K, et al. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator in-hibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000; 49: 666-671.
31. Eriksson P, Van Harmelen V, Hoffstedt J, et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000; 83: 545-548.
32. Vohl MC, Sladek R, Robitaille J, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res 2004; 12: 1217-1222.
33. Lindeman JH, Pijl H, Toet K, et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes 2007; 31: 1671-1679.
34. Yudkin JS, Coppack SW, Bulmer K, et al. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thromb Res 1999; 96: 1-9.
35. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
36. Auerbach AD, Goldman L. beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. J Am Med Assoc 2002; 287: 1435-1444.
37. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-2618.
38. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10: 83-92.
39. Eren M, Painter CA, Atkinson JB, et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 491-496.
40. Moor E, Blomback M, Silveira A, et al. Haemostatic function in patients undergoing coronary artery bypass grafting: peroperative perturbations and relations to saphenous vein graft closure. Thromb Res 2000; 98: 39-49.
41. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.